The Liver Biopsy Market continues to gain traction globally as the need for accurate liver disease diagnosis rises across healthcare systems. Valued at USD 0.90 billion in 2023, the market is estimated to reach USD 1.65 billion by 2032, supported by a stable CAGR of 6.99% from 2024 to 2032. Increasing cases of NAFLD, autoimmune hepatitis, and chronic liver complications are prompting healthcare providers to adopt more reliable biopsy procedures for early and precise detection.
A major contributor to market expansion is the widespread use of percutaneous biopsy. This segment dominated nearly 60% of total procedures in 2023 due to its minimally invasive nature and quick recovery time for patients. Growing reliance on imaging guidance has improved accuracy and reduced complications, accelerating the adoption of this technique across hospitals and clinics worldwide. As imaging technologies evolve, the demand for well-established biopsy methods is expected to remain strong.
Meanwhile, transjugular biopsy continues to attract attention as the fastest-growing segment. With an annual growth rate nearing 8%, this method is preferred for patients with bleeding risks or coagulopathies. It allows safe sampling and minimizes complications, which is highly valuable for clinicians handling complex liver cases. Increasing awareness about the benefits of advanced biopsy techniques is encouraging both providers and patients to explore safer diagnostic alternatives.
Get free Sample Report@ https://www.snsinsider.com/sample-request/2796
The market’s growth is also strongly linked to rising global cases of NAFLD, which accounted for approximately 45% of total liver biopsy indications in 2023. The steady rise in obesity, diabetes, and metabolic disorders is contributing to higher NAFLD prevalence, placing significant pressure on healthcare systems to diagnose patients earlier. The autoimmune hepatitis segment is also expanding rapidly, marked by a 9% annual growth rate as diagnostic awareness and clinical screening improve.
In terms of end users, hospitals and clinics accounted for nearly 70% of the market share in 2023. Their access to advanced imaging tools, trained specialists, and structured diagnostic workflows makes them the preferred destination for biopsy procedures. However, diagnostic centers are rapidly emerging as a strong competitor, with an impressive 10% annual growth rate. These centers offer faster access, specialized services, and improved convenience for patients seeking outpatient biopsy solutions.
North America led the global Liver Biopsy Market in 2023, capturing almost 45.7% of the total share. The region’s strong healthcare infrastructure, high liver disease prevalence, and supportive research environment continue to drive adoption. Rising cases of alcoholic liver disease and viral hepatitis, combined with increasing health expenditure, contribute significantly to regional growth. Public health data indicates thousands of annual deaths in the United States linked to liver disease, reinforcing the need for early and accurate diagnostic procedures.
Europe continues to be an influential market as well, with Germany, France, and the United Kingdom contributing heavily to procedure volumes. High utilization of diagnostic technologies in tertiary healthcare institutions, growth in chronic disease research, and an expanding ecosystem of medical equipment manufacturers support market expansion. Reports indicating tens of thousands of deaths annually linked to liver diseases highlight the urgency for improved screening and diagnostic accuracy across Europe.
The Asia Pacific region is projected to experience the strongest growth through 2032. Key economies including China, Japan, and India are making substantial investments in healthcare infrastructure, research, and advanced diagnostic tools. Japan leads the region, supported by high chronic liver disease prevalence and strong adoption of modern technologies. Notably, nearly a quarter of Japan’s population is estimated to be affected by chronic liver conditions, intensifying demand for faster and more reliable diagnostic methods. As healthcare modernization accelerates across Asia Pacific, greater access to biopsy devices and improved medical awareness are expected to fuel robust market expansion.
Overall, the Liver Biopsy Market is positioned for healthy growth over the next decade. Advancements in minimally invasive techniques, expansion of diagnostic centers, rising patient awareness, and improved imaging accuracy are combining to strengthen market demand. As chronic liver diseases continue to emerge as a major global health burden, the need for timely and precise biopsy procedures is expected to remain a central focus for healthcare systems.
FAQ Section
1. What is driving the growth of the Liver Biopsy Market?
Rising NAFLD cases, advanced imaging technologies, and expanding diagnostic infrastructure are key drivers boosting global market growth.
2. Which biopsy type holds the largest market share?
Percutaneous biopsy holds the largest share, favored for its minimally invasive approach and reliable accuracy.
3. Which indication is most common for liver biopsy procedures?
NAFLD represents the largest indication due to increasing obesity and metabolic-related conditions worldwide.
4. Which region leads the global market?
North America leads the market because of high disease prevalence, advanced healthcare facilities, and strong research support.
5. Which end user segment is growing fastest?
Diagnostic centers are growing fastest due to rising demand for outpatient services and specialized testing facilities.
Other Trending Reports
Microdermabrasion Devices Market
Advance Directives Market Growth
Microbial Fermentation Technology Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
